PRESS RELEASE published on 09/09/2024 at 22:43, 1 year 4 months ago Rapport CAC sur l'information financière semestrielle 2024
BRIEF published on 09/09/2024 at 22:40, 1 year 4 months ago ABIVAX présente ses résultats semestriels 2024 Résultats Semestriels Abivax Cybersécurité Contrôle Interne Défaillances
BRIEF published on 09/09/2024 at 22:40, 1 year 4 months ago ABIVAX presents its 2024 half-year results Cybersecurity Abivax Half-year Results Internal Control Failures
PRESS RELEASE published on 09/09/2024 at 22:35, 1 year 4 months ago Lettre d'affirmation sur les comptes semestriels 2024 Lettre d'Affirmation Comptes Semestriels Consolidés IFRS de ABIVAX S.A. pour la période du 1 janvier 2024 au 30 juin 2024, validée par PwC Audit et Agili(3F) Audit IFRS Comptes Semestriels ABIVAX S.A. PwC Audit Agili(3F) Audit
PRESS RELEASE published on 09/09/2024 at 22:18, 1 year 4 months ago Rapport financier semestriel 2024
BRIEF published on 09/09/2024 at 22:06, 1 year 4 months ago Résultats financiers d'Abivax pour le premier semestre 2024 Résultats Financiers Biotechnologie Abivax Premier Semestre 2024 Mécanismes Immunitaires
BRIEF published on 09/09/2024 at 22:06, 1 year 4 months ago Abivax financial results for the first half of 2024 Financial Results Biotechnology Abivax First Half Of 2024 Immune Mechanisms
PRESS RELEASE published on 09/09/2024 at 22:01, 1 year 4 months ago Abivax presents first-half 2024 financial results Abivax presents first-half 2024 financial results with a cash balance of EUR 222M at June 30, 2024. The company focuses on developing therapies for chronic inflammatory diseases Financial Results Abivax Therapeutics Chronic Inflammatory Diseases EUR 222M
PRESS RELEASE published on 09/09/2024 at 22:01, 1 year 4 months ago Abivax présente ses résultats financiers du premier semestre 2024 Abivax présente ses résultats financiers semestriels 2024 avec une trésorerie de 222 millions d'euros au 30 juin 2024, assurant le financement jusqu'au Q4 2025 Résultats Financiers Abivax Bilan Trésorerie Dépenses
BRIEF published on 08/29/2024 at 18:05, 1 year 5 months ago ABIVAX : État des actions et des droits de vote au 31 juillet 2024 Euronext Paris Droits De Vote Actions Abivax Réglementaire
Published on 02/06/2026 at 00:00, 51 minutes ago LIR Life Sciences Commences Project Phase 2 Peptide Design Program with Neuland Laboratories
Published on 02/05/2026 at 23:15, 1 hour 36 minutes ago Amarc Further Expands Its Toodoggone Technical Team
Published on 02/05/2026 at 23:00, 1 hour 51 minutes ago Grounded People Announces Non-Brokered Private Placement and Strategic Review
Published on 02/05/2026 at 21:00, 3 hours 51 minutes ago Kidoz Welcomes CloudX Innovation Driving Fairer Mobile Advertising Auctions
Published on 02/05/2026 at 18:50, 6 hours 1 minute ago Athena Gold Provides Exploration Update From Nevada and Ontario
Published on 02/05/2026 at 19:27, 5 hours 23 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 02/05/2026 at 18:46, 6 hours 4 minutes ago EQS-Adhoc: Mayr-Melnhof Karton AG: Impairment requirements impact profit for the financial year 2025
Published on 02/05/2026 at 18:09, 6 hours 41 minutes ago Funding Circle Holdings plc: POS-Transaction in Own Shares
Published on 02/05/2026 at 17:55, 6 hours 55 minutes ago Piramal Critical Care and Blue-Zone Technologies collaborate to capture, collect and recycle waste anaesthesia gas
Published on 02/05/2026 at 17:40, 7 hours 11 minutes ago BROADPEAK SA: Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social au 01.02.26.
Published on 02/05/2026 at 19:15, 5 hours 36 minutes ago ALTAREA : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 02/05/2026 at 19:15, 5 hours 36 minutes ago ALTAREA : DÉCLARATION MENSUELLE DES OPÉRATIONS RÉALISÉES PAR LA SOCIÉTÉ SUR SES PROPRES TITRES JANVIER 2026
Published on 02/05/2026 at 19:15, 5 hours 36 minutes ago ALTAREIT : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
